


## ▪ Tyr-Nras cells

Mouse Tyr-Nras cells were isolated from a primary melanoma of a C57BL/6 mouse. They were authenticated by Microsynth.

## ▪ Tumour growth *in vivo*

Tumor fragments were collected from an *in vivo* tumor and surgically implanted subcutaneously in the right flank of C57BL/6 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.

The mice bearing Tyr-Nras tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.



**Figure 1:** Tumour growth curve of the Tyr-Nras cells as subcutaneous tumours  
Mean  $\pm$  SEM (n=6; take rate 100%)

## ▪ Drug Responses

Anti-PD1 12.5 mg/kg  $\rightarrow$  Response  
Anti-PDL1 12.5 mg/kg  $\rightarrow$  Response

Immunophenotyping data of the lymphoid and myeloid lineage are available upon request.

Antineo has developed models of secondary resistance to anti-PD1 or anti-PDL1 (ID Tyr-Nras anti-PD1R and Tyr-Nras anti-PDL1R). These models have been developed *in vivo* without genetic modifications.